Ozempic Kidney Trial Sinks Dialysis Stocks

The weight-loss revolution is shaking another industry.

Kidney-dialysis stocks sank Wednesday after Novo Nordisk (NVO), (DK: NOVO.B) said a trial showed its blockbuster diabetes drug Ozempic could delay the progression of kidney disease.